GPD2 and prostate carcinoma: Strikingly, the proportion between GPhigh and GPlow significantly differed between cell lines—GPlow content was higher in the prostate cancer cell line, representing 19.4% ± 9.3% in PNT1A and 58.0% ± 19% in LNCaP of the total mGPDH content (Figure 1F).